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Conclusions: The most common SUV descriptors as well as 
the volume of the involved lymph nodes of NSCLC patients 
are significant prognostic factors for overall survival for 
NSCLC. Likelihood of a worse prognosis increases with an 
increase of the mean SUV of the nodes. This is consistent 
with our hypothesis that there is more PET-related prognostic 
information in the nodes compared to the primary tumor.  
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Purpose/Objective: Stereotactic body radiotherapy (SBRT) is 
the treatment of choice in medically inoperable patients with 
stage I NSCLC. Today, SBRT is used with increasing frequency 
for pulmonary metastases: however, dose prescriptions are 
adapted from primary NSCLC experiences without their 
validation for metastases. It was therefore the aim of this 
study to analyze a potential dose-effect relationship for local 
tumor control in SBRT for pulmonary metastases and compare 
results to SBRT for stage I NSCLC. 
Materials and Methods: This retrospective multi-institutional 
study is based on 582 and 964 patients treated with SBRT for 
stage I NSCLC and pulmonary metastases at 13 centres; only 
patients with follow-up >6 months were analyzed resulting in 
399 and 525 patients, respectively. Patients with primary 
NSCLC and pulmonary metastases were treated with a 
median of 3 (range 1-17) and 3 (1-12) fractions to a total 
dose of 60Gy (range 19-86) and 55Gy (16-80) (maximum PTV 
dose at isocenter; PTV-max), respectively. BED was 
calculated using the LQ-model with α/β=10Gy resulting in 
PTV-max doses of 168Gy (48-263) and 138Gy (24-288) BED for 
primary NSCLC and metastases, respectively. Dose-effect 
models were compared using the second-order bias corrected 
Akaike Information Citerion (AICC). We used Bayesian logistic 
regression to estimate regression parameters and their 
standard errors. 
Results: Median tumor diameter was 2.6cm (0.8-4.8) and 
1.9cm (0.4-9.0) for patients with primary NSCLC and 
pulmonary metastases, respectively (p<0.001, Wilcoxon rank 
sum test); tumor diameter was lacking in 47% (primary 
NSCLC) and 12% (pulmonary metastases) of the patients. Most 
frequent histologies for pulmonary metastases were NSCLC 
(28%), colorectal (25%) and renal cell cancer (11%). Median 
follow-up was 19 months (6-139; primary NSCLC) and 16 
months (6-125; pulmonary metastases) (p=0.15). For 
pulmonary metastases, a strong dose response relationship 
was observed (evidence ratio 98.6), but only for PTV-max 
BED and not for the PTV encompassing BED; the latter is in 
contrast to findings from SBRT for primary NSCLC, where a 
strong evidence for a minimum PTV dose-effect was observed 
(Guckenberger et al. Radiother Oncol 2013). Overall, there 
was no difference in the dose response relationship between 
primary NSCLC and pulmonary metastases: the PTV-max BED 
required for 90% TCP was 176±17Gy and 167±18 Gy for 
primary NSCLC and pulmonary metastases, respectively. 
Conclusions: A significant dose-response relationship was 
observed in SBRT for pulmonary metastases with local tumor 
control as endpoint. The observed dose response relationship 
was not different to primary stage I NSCLC. We will, 
however, further investigate the influence of histology and 
tumor size on the dose-effect relationship in pulmonary 
metastases.  
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The incidence of breast cancer is rising in the elderly, 
reflecting the age related incidence of the disease and, in 
the UK, the impact  of  the breast screening programme. The 
evidence base for the role of postoperative radiotherapy (RT) 
after breast conserving surgery  in older patients has been 
limited, in part reflecting the historical exclusion of the 
elderly from randomised trials. Extrapolating outcomes from 
younger to older patients may not be valid. In older patients 
there are also competing risks of non breast cancer mortality. 
The Oxford overview (1) of over 10,000 women treated with 
breast conserving surgery with or without adjuvant 
radiotherapy shows that RT halves the risk of first recurrence 
(most of which are local). However the absolute reduction in 
risk of recurrence from RT is very modest in older good 
prognosis patients. The main source of level 1 evidence in 
older patients is the CALGB 9343 trial (1) which randomised 
over 700 women =/> 70 years with T1, NO,MO hormone 
receptor positive breast cancer treated by breast conserving 
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surgery and 5 years of adjuvant tamoxifen to postoperative 
whole breast irradiation or no further therapy. At a median 
follow up of 5.7 years the local recurrence rate was reduced 
by RT from 4% to 1%. However there has been limited impact 
on practice.  A survey of Medicare patients (2) who met the 
eligibility criteria of the CALGB 9943 trial showed 
approximately a 3% reduction in use of adjuvant radiotherapy 
in a period following the publication of the 5 year results of 
the CALBG trial. The reasons for this limited impact on 
practice are uncertain.The 10 year results of the CALGB 9943 
(3) show that the difference in local control has widened(2% 
vs 9%). In the UK postoperative radiotherapy remains the 
standard of care for all patients technically suitable for 
radiotherapy irrespective of age and other clinico-
pathological risk factors. The benefits of adjuvant 
radiotherapy on local control have to be balanced against the 
issues of comorbidity, breast toxicity, risks of second 
malignancy(4) and the costs of radiotherapy. Results will be 
presented from the international PRIME 2 trial in over 1300 
hormone receptor positive, T1-2 (up to 3cm) pNO  breast 
cancer in women =/> 65 years treated by breast conserving 
surgery and adjuvant endocrine therapy with or without 
postoperative radiotherapy (5). A case can be made for 
offering selected older patients the option of the omission of 
RT. Techniques of partial breast irradiation are also being 
investigated which might be more convenient and less morbid 
than whole breast irradiation. 
There is limited level 1 evidence on the impact on quality of 
life of adjuvant radiotherapy. The PRIME quality of life trial 
suggests that there is no significant difference in global 
quality of life in early breast cancer patients treated by 
breast conserving surgery with or without whole breast 
irradiation(6). 
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Hypofractionation has lately been implemented as standard 
treatment in the adjuvant setting as well as in radical 
radiotherapy for various solid tumors such as in breast and 
lung carcinomas. Also for metastatic disease in the liver or 
brain, hypofractionated stereotactic radiotherapy has proven 
effective for both palliative purposes and sometimes cure. 
Palliative schedules have conventionally been designed to 
deliver sufficient radiation dose within a short period of time 
to achieve optimal palliation with particular consideration to 
life expectancy. Such treatment strategies may be assigned 
to frail and elderly patients at the expense of curative 
fractionation schedules, particularly for logistic reasons in 
those with impaired functional conditions, that the patient 
may better comply to treatment. However, data from 
DAHANCA showed no impact of age, comorbidity, or WHO 
performance status on delay of treatment in patients 
undergoing a fast-track work-up for head and neck cancer 
(H&N), and elderly patients (above 70) demonstrated 
equivalent compliance to prescribed radical radiation 
treatment compared to younger patients which was further 
translated into similar cancer-specific survival figures 
between the age-groups. However, if for a particular clinical 
reason a reduced treatment time is opted for in an the 
elderly H&N patient, several considerations should  be made. 
Whether the intention of treatment is palliative or curative, 
treatment volume and fractionation schedules are obviously 
related to toxicity. Elderly H&N patients with a low 
propensity for HPV-derived carcinomas have generally lower 
rates of neck metastases than younger patients (N0-1 below 
20% vs 35%) which defines a smaller target area. With modern 
diagnostic procedures and cone-beam based adaptive IMRT 
techniques, both dose-planning and execution of radiation 
treatment have become more precise which elderly patients 
may profit from, particularly if elective radiation is omitted, 
similar to stereotactic strategies. Delivery of 30 Gy in 10 
fraction over 2 weeks, or 20 Gy in 5 fx, confer a dose-
intensity much higher than conventional or accelerated 
regimens and, consequently, increases the risk of severe 
mucositis. We have adopted a hypofractionated schedule 
from the DAHANCA 2 trial consisting of 52 Gy in 13 fractions 
with two weekly fractions (8 Gy per week). This has secured 
a tolerable treatment schedule with a considerably high 
radiobiological dose for potential cure. Toxicity has been 
mild in comparison to standard fractionation, and the 
schedule has been employed for patients considered 
unsuitable for standard treatment. IMRT and VMAT are easily 
applied in hypofractionated regimens for elderly patients 
since these techniques have become standard of care, and 
acceptable toxicity and cure rates are expected. 
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Rapid population ageing in most area of the developed world 
substantially contributes to the significant increase in the 
cancer burden in the elderly. In the subgroup of cancer 
patients’ (pts) over-75 years of age, for ex, prostate cancer 
(PCa) becomes the most common tumour diagnosed in men in 
Europe and North America. On the other hand, life 
expectancy is increasing in western countries and this 
translates in a general feeling that curative treatment 
options should be offered even to elderly pts independently 
of their chronological age. Oncologists treating a geriatric 
population of pts face several major issues when developing 
